secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolent Health, Inc. (EVH)
CIK:        0001628908
Form:       8-K
Filed at:   2026-08-06T11:03:53+00:00
Accession:  0001628908-26-000084
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolent Q2 revenue $652.5M (+47% YoY); net loss narrows; new oncology partnership to add $300M annual revenue
--------------------------------------------------------------------------------

- Revenue $652.5M vs $444.3M YoY; net loss attributable to common $28.4M vs $51.1M.
- Adjusted EBITDA $28.1M (4.3% margin) vs $37.5M (8.5% margin) YoY; Medical Expense Ratio 95.3% vs 80.0%.
- Guides 2027 revenue growth >25% vs 2026; midpoint of 2027 Adjusted EBITDA at or above $150M.
- New Oncology Performance Suite partnership covering ~1.5M lives, expected launch Dec 2026, ~$300M annualized revenue.
- Existing STSS client expands; annualized revenue <$5M; company evaluating debt reduction initiatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628908/000162890826000084/0001628908-26-000084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628908/000162890826000084/evh-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001628908-26-000084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer